JP2022533092A5 - - Google Patents

Info

Publication number
JP2022533092A5
JP2022533092A5 JP2021567935A JP2021567935A JP2022533092A5 JP 2022533092 A5 JP2022533092 A5 JP 2022533092A5 JP 2021567935 A JP2021567935 A JP 2021567935A JP 2021567935 A JP2021567935 A JP 2021567935A JP 2022533092 A5 JP2022533092 A5 JP 2022533092A5
Authority
JP
Japan
Prior art keywords
caar
cells
domain
acid sequence
achr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021567935A
Other languages
English (en)
Japanese (ja)
Other versions
JP7649755B2 (ja
JP2022533092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032486 external-priority patent/WO2020231999A1/en
Publication of JP2022533092A publication Critical patent/JP2022533092A/ja
Publication of JP2022533092A5 publication Critical patent/JP2022533092A5/ja
Application granted granted Critical
Publication of JP7649755B2 publication Critical patent/JP7649755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021567935A 2019-05-13 2020-05-12 アセチルコリン受容体キメラ自己抗体受容体細胞の組成物および方法 Active JP7649755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847121P 2019-05-13 2019-05-13
US62/847,121 2019-05-13
PCT/US2020/032486 WO2020231999A1 (en) 2019-05-13 2020-05-12 Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells

Publications (3)

Publication Number Publication Date
JP2022533092A JP2022533092A (ja) 2022-07-21
JP2022533092A5 true JP2022533092A5 (https=) 2023-05-19
JP7649755B2 JP7649755B2 (ja) 2025-03-21

Family

ID=73289319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021567935A Active JP7649755B2 (ja) 2019-05-13 2020-05-12 アセチルコリン受容体キメラ自己抗体受容体細胞の組成物および方法

Country Status (10)

Country Link
US (2) US20220242931A1 (https=)
EP (1) EP3969587A4 (https=)
JP (1) JP7649755B2 (https=)
KR (1) KR20220007675A (https=)
CN (2) CN121204097A (https=)
AU (1) AU2020275776A1 (https=)
CA (1) CA3139131A1 (https=)
IL (1) IL287724A (https=)
MX (1) MX2021013949A (https=)
WO (1) WO2020231999A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022136503A1 (en) * 2020-12-22 2022-06-30 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
CN116997654A (zh) * 2021-03-17 2023-11-03 第一三共株式会社 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因
IL314801A (en) * 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
WO2025072450A1 (en) 2023-09-26 2025-04-03 Werewolf Therapeutics, Inc. Enhanced adoptive cell therapy
WO2025249959A1 (ko) * 2024-05-30 2025-12-04 (주)메디톡스 융합단백질 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132972A0 (en) * 1999-11-16 2001-03-19 Yissum Res Dev Co Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
WO2004009775A2 (en) * 2002-07-19 2004-01-29 Targacept, Inc. Methods and compositions relating to chimeric nicotinic receptor subunits
KR100719020B1 (ko) * 2005-09-28 2007-05-17 광주과학기술원 재조합 아세틸콜린 수용체 폴리펩티드, 폴리펩티드 유도체및 이를 유효성분으로 포함하는 중증근무력증 치료제
JP4495776B1 (ja) 2009-07-30 2010-07-07 日本製薬株式会社 融合蛋白質
KR20140004174A (ko) * 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN113604491A (zh) * 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
RU2018140056A (ru) * 2016-04-15 2020-05-15 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
CN109996812A (zh) 2016-09-08 2019-07-09 加利福尼亚大学董事会 用于诊断和治疗重症肌无力的肽及其用途
WO2018127585A1 (en) * 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells

Similar Documents

Publication Publication Date Title
JP2021526795A5 (https=)
JP2022533092A5 (https=)
JP2021522790A5 (https=)
KR100454396B1 (ko) 단백질-티로신키나제키메라에의한세포면역성의방향전환
ES2302811T3 (es) Procedimiento para proteger transplantes de islotes alogenicos usando moleculas mutantes soblules ctla4.
Wozniak et al. Primary structure analysis of an integral membrane glycoprotein of the nuclear pore.
TWI311564B (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
CN115175935A (zh) Cal-t构建体及其用途
UA125207C2 (uk) Комбінована терапія для лікування злоякісної пухлини
EA020508B1 (ru) ВЫДЕЛЕННЫЕ АНТИТЕЛА К Sp35 И ИХ ПРИМЕНЕНИЕ
CN102088990A (zh) 癫痫的治疗
JP2019513394A5 (https=)
JP2008537736A (ja) 抗原特異的ｔ細胞の操作に有用な組換えｍｈｃ分子
JP2023500338A5 (https=)
AU676680B2 (en) Isolation, characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin
CA2429579A1 (en) Truncated cd200
EP3898665B1 (en) Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CN114249832B (zh) 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
US20160318988A1 (en) T cell receptor binding to alwgpdpaaa, derived from human pre-pro insulin (ppi) protein
JP2022526194A (ja) Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法
CN119095869A (zh) 用于预防和/或治疗炎症性病症的靶向共刺激分子的具有嵌合抗原受体的调节性t细胞
CA2571350A1 (en) Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins
Araga et al. A complementary peptide vaccine that induces T cell anergy and prevents experimental allergic neuritis in Lewis rats
WO2010137022A1 (en) Gpr54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities
KR102425014B1 (ko) Calcyon 및 Hevin의 결합 조절제를 유효성분으로 포함하는 시냅스 형성 장애에 의한 신경질환의 예방 또는 치료용 조성물